Kymera Therapeutics Receives FDA Fast Track Status for KT-621 in Asthma Treatment
Tuesday, April 14, 2026
Kymera Therapeutics, Inc. has received Fast Track designation from the U.S. Food and Drug Administration for KT-621, an oral STAT6 degrader developed to treat moderate to severe eosinophilic asthma.
KT-621 is currently being evaluated in two global Phase 2b studies, including one focused on asthma. Despite the availability of inhalers and injectable biologics, there remains a need for effective and convenient oral treatment options for patients with poorly controlled disease.
Preclinical and early clinical findings have shown promising results. The therapy demonstrated reductions in fractional exhaled nitric oxide, a marker of lung inflammation, and improvements in asthma control in a subset of patients during a Phase 1b study in atopic dermatitis. These findings support its potential to target Type 2 inflammation across multiple conditions.
The ongoing BREADTH Phase 2b trial in asthma is expected to report results in late 2027. Another Phase 2b study, BROADEN2, is evaluating KT-621 in atopic dermatitis, with data anticipated by mid-2027. These trials are intended to support further development and guide dosing for future Phase 3 studies.
The FDA’s Fast Track programme is designed to accelerate the development and review of medicines that address serious conditions and unmet medical needs. It allows for closer interaction with the regulator and may enable faster approval pathways if requirements are met.
KT-621 is a once-daily oral therapy that targets STAT6, a key driver of Type 2 inflammation linked to several immune-related diseases. Early studies have shown reductions in inflammatory biomarkers, improvements in clinical outcomes and a favourable safety profile. The therapy is being developed for a range of conditions, including asthma and atopic dermatitis.
Source: globenewswire.com
